If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
Hospital-acquired pneumonia, is the most common nosocomial infection—and the deadliest.
In the COVID-19 pandemic years 2020 to 2021, IPD incidence dipped to a low of 1.6 per 100,000 children.
The level is slightly higher in school-age kids, but similar to the prepandemic period.
Before COVID, Denmark experienced Mycoplasma outbreaks every 3 to 7 years.
Chinese officials told the WHO that the increase in respiratory illness in children is linked to increased circulation of Mycoplasma pneumoniae and an uptick in flu, RSV, and adenovirus.
Media reports describe overwhelmed children's hospitals in multiple locations in China.
The award of $1.75 million will support development of a therapeutic that could restore the activity of commonly used antibiotics for community-acquired pneumonia.
The company is seeking the FDA's go-ahead for first-in-human trials in patients with hospital-acquired and ventilator-associated pneumonia.
If approved, the product would be the first pneumococcal conjugate vaccine specifically designed for adults.